MOTS-c exercise claims run ahead of the human evidence. The peptide is often called an exercise mimetic—a substance described as copying some biological signals of exercise—but no published human trial shows that taking MOTS-c improves endurance, strength, recovery, or workout performance. The phrase comes from two narrower findings: exercise raised the MOTS-c that people made themselves in a small cycling study, and giving MOTS-c to mice helped some treated animals run longer. Those are interesting signals. They are not a human performance result.

Why MOTS-c gets called an exercise mimetic

MOTS-c is a peptide, a short chain of amino acids, encoded in mitochondrial DNA. Mitochondria are the parts of cells that manage energy. The story of who discovered MOTS-c begins with a 2015 paper from Changhan Lee, Pinchas Cohen, and colleagues.

That Cell Metabolism study connected MOTS-c with skeletal muscle and AMPK, an energy-sensing switch inside cells. The researchers found that MOTS-c interrupted part of the folate cycle, which helps cells make DNA building blocks. That detour led to AMPK activation. The treatment experiments were in mice and cells, not exercising people.

The phrase “exercise mimetic” is therefore shorthand for a possible overlap in biology. It does not mean MOTS-c reproduces the many things movement does for the heart, lungs, bones, brain, balance, and muscles. It also does not establish that a manufactured dose has the same effect as the MOTS-c the body makes during exercise.

What the MOTS-c exercise study actually tested

The study behind most exercise claims was published in Nature Communications in 2021. Its human experiment enrolled 10 healthy, sedentary young men. They completed an intense cycling session while researchers measured the MOTS-c already present in blood and muscle. Nobody in the human group received MOTS-c.

The paper reported that MOTS-c in muscle rose 11.9-fold after exercise. In plasma, the liquid part of blood, it rose 1.6-fold during exercise and 1.5-fold just after, then returned to baseline after four hours. That shows exercise can change the body’s own MOTS-c signal. It does not show that taking MOTS-c makes exercise easier or more productive.

The same paper did administer MOTS-c to mice. Across experiments in young, middle-aged, and old animals, researchers reported changes in running performance and muscle metabolism. In one older group, treated mice ran about twice as long and more than twice as far as untreated mice. Every treatment-performance number in that paper came from mice. The broader MOTS-c evidence keeps those species separate.

Does MOTS-c improve exercise performance in people?

There is no published human performance trial showing that it does. No completed study has compared administered native MOTS-c with placebo for running time, strength, recovery, oxygen use, or training gains. Measurements of a natural peptide after cycling are not a treatment trial. Mouse treadmill results cannot supply the missing human answer.

CB4211 is sometimes offered as the human evidence. It is an analog—a deliberately modified relative of MOTS-c—not the native peptide. CohBar’s Phase 1a/1b program enrolled 88 people overall. Its four-week Phase 1b portion involved 20 adults with obesity and fatty liver disease and measured safety, liver markers, glucose, body weight, and liver fat. It did not test exercise performance. The August 10, 2021 company release reported topline findings, but no peer-reviewed efficacy paper followed.

This gap matters for safety too. Without a completed trial of administered native MOTS-c, there is no reliable human rate for side effects during training or at rest. The MOTS-c side-effects evidence explains why an empty column means “not measured,” not “risk-free.”

People also group MOTS-c with SS-31 because both are discussed in mitochondrial medicine. That shared category does not make them interchangeable. SS-31 is a different peptide with its own research program, so its human data cannot answer whether MOTS-c changes a workout.

What changed in the 2026 FDA review

As of September 18, 2026, the day this article was written, the FDA’s July 23 Pharmacy Compounding Advisory Committee meeting had considered MOTS-c free base and acetate for the 503A Bulks List, a federal list used for certain traditional compounding decisions. This was a compounding review, not a review of athletic performance.

In its meeting presentation, FDA staff said they had not identified clinical studies or human exposure data for drug products containing those MOTS-c substances by any route. Staff proposed not adding the two forms to the list. The committee gives advice; the meeting itself was not final rulemaking or a drug approval.

MOTS-c has never had a U.S. FDA-approved product. The compounded formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

Why WADA prohibits MOTS-c

For a tested athlete, the evidence question and the rule question have different answers. As of September 18, 2026, the day this article was written, the 2026 World Anti-Doping Agency Prohibited List, effective January 1, 2026, names MOTS-c in section S4.4.1 among AMPK activators. That section is prohibited at all times, both in and out of competition.

This classification does not prove that MOTS-c improves human performance. Anti-doping rules can cover a substance based on its biological class and performance potential before a treatment effect has been shown in a clinical trial. A prescription does not erase the sport rule. The drug-testing explainer for BPC-157 walks through how WADA’s year-round prohibition and therapeutic-use process work; the exact category differs for MOTS-c.

What belongs in a MOTS-c conversation

The honest starting point is the goal. “More endurance,” “faster recovery,” and “better energy” sound similar online, but they are different clinical questions. The research cannot yet predict which, if any, would change after administered MOTS-c in a person. It also cannot supply a human exercise dose or a workout schedule.

A licensed provider reviews every request and not everyone qualifies. That review is where medical history, current medicines, athletic testing rules, the thin human evidence, and what could be monitored belong. The mouse findings explain why researchers are interested. They do not decide what is appropriate for the person asking.